Literature DB >> 9389554

Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action.

S Mohseni-Zadeh1, M Binoux.   

Abstract

With a view to determining the mechanisms by which insulin-like growth factor binding protein-3 (IGFBP-3) and its proteolytic fragments modulate IGF action, we used a fibroblast cell line to investigate the possibility of an interaction with the type 1 IGF receptor (IGFR-1). In competitive binding experiments, IGFBP-3 was as potent as unlabelled IGF-I in displacing its truncated analogue, 125I-des(1-3)IGF-I, which has weak affinity for IGFBPs, from its binding to the cell surface. None of the proteolytic fragments of IGFBP-3 tested affected this binding. IGFBP-3 had no effect on insulin binding to its receptor. At 10 nM, IGFBP-1 was ineffective where IGFBP-3 provoked 90% displacement of 125I-des(1-3)IGF-I, but it was equally potent in displacing 125I-IGF-I. At the same concentration, binding of 125I-des(1-3)IGF-I to free IGFBP-3 in the supernatant was only 2%. After pre-incubation of the cells with 125I-des(1-3)IGF-I, low concentrations of IGFBP-3 were as potent as IGF-I in dissociating IGFR-1-bound ligand. After pre-incubation of cells with IGFBP-3, washing and then incubation with 125I-des(1-3)IGF-I, inhibition by low IGFBP-3 concentrations was suppressed, but some degree of inhibition by high concentrations persisted. At these high concentrations, addition of IGF-I restored binding owing to uptake of cell-associated IGFBP-3. The present results provide the first evidence that IGFBP-3 may inhibit IGF binding to IGFR-1, and hence limit IGF action via a cellular mechanism that is different from the extracellular mechanism of sequestration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9389554     DOI: 10.1210/endo.138.12.5714

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

2.  IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1-induced mitogenesis.

Authors:  Astrid C Baege; Gary L Disbrow; Richard Schlegel
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

Review 3.  Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease.

Authors:  Sonu Kashyap; Julianna D Zeidler; Claudia C S Chini; Eduardo Nunes Chini
Journal:  Cell Signal       Date:  2020-06-20       Impact factor: 4.315

4.  Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism.

Authors:  Shoshana Yakar; Clifford J Rosen; Mary L Bouxsein; Hui Sun; Wilson Mejia; Yuki Kawashima; Yingjie Wu; Kelly Emerton; Valerie Williams; Karl Jepsen; Mitchell B Schaffler; Robert J Majeska; Oksana Gavrilova; Mariana Gutierrez; David Hwang; Patricia Pennisi; Jan Frystyk; Yves Boisclair; John Pintar; Héctor Jasper; Horacio Domene; Pinchas Cohen; David Clemmons; Derek LeRoith
Journal:  FASEB J       Date:  2008-10-24       Impact factor: 5.191

5.  Recombinant insulin-like growth factor-I (IGF-I) production in Super-CHO results in the expression of IGF-I receptor and IGF binding protein 3.

Authors:  N A Sunstrom; M Baig; L Cheng; D Payet Sugyiono; P Gray
Journal:  Cytotechnology       Date:  1998-11       Impact factor: 2.058

6.  Impaired expression of insulin-like growth factor-1 system in skeletal muscle of amyotrophic lateral sclerosis patients.

Authors:  Christian Lunetta; Massimo Serafini; Alessandro Prelle; Paolo Magni; Elena Dozio; Massimiliano Ruscica; Jenny Sassone; Clarissa Colciago; Maurizio Moggio; Massimo Corbo; Vincenzo Silani
Journal:  Muscle Nerve       Date:  2012-02       Impact factor: 3.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.